Search - tctmd.com

Displaying 681 - 700 of 868

Sort: Relevancy | Date

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

Presenter: David Antoniucci

October 28, 2013

Presentation TCT 2013

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Presenter: Martin Leon

October 28, 2013

Presentation TCT 2013

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

Presenter: Adnan Kastrati

October 28, 2013

Presentation TCT 2013

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Presenter: David Cohen

October 28, 2013

Presentation TCT 2013

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Presenter: Gregg Stone

October 28, 2013

Presentation TCT 2013

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Presenter: Young-Hak Kim

October 28, 2013

Presentation TCT 2013

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Presenter: Eulogio Garcia

October 28, 2013

Presentation TCT 2013

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Presenter: Bernard Chevalier

October 28, 2013

Presentation TCT 2013

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

Presenter: Gregory Pavlides

October 28, 2013

Presentation TCT 2013

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Presenter: Piotr Buszman

October 28, 2013

News Conference News TCT 2013

Memories of TCT 1988 and Beyond: Marvin L. Woodall

October 28, 2013

News Conference News TCT 2013

Cre8, BioFreedom Polymer-Free DES Show Promise

October 28, 2013

News Conference News TCT 2013

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

October 28, 2013

News Conference News TCT 2013

Bioresorbable Scaffold Stands Ground Next to Current DES

October 28, 2013

News Conference News TCT 2013

ABSORB III and IV Trials Aim to Prove Superiority of BVS

October 28, 2013

Presentation TCT 2013

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Presenter: Thomas Zeller

October 27, 2013

Presentation TCT 2013

Management of Patients with Atrial Fibrillation and Stents

Presenter: Neal Kleiman

October 27, 2013

Presentation TCT 2013

Bare Metal and Drug-Eluting Stents: Indications, Outcomes, Complications

Presenter: Sahil Parikh

October 27, 2013

Presentation TCT 2013

The Impact Of First- versus Second-Generation Drug-Eluting Stents On Immediate- and Intermediate-Term Outcomes In A Complex ST-Segment Elevation Myocardial Infarction Population

Presenter: Joshua Loh, Hironori Kitabata, Israel Barbash, Danny Dvir, Salem Badr, Rebecca Torguson, Kenneth Kent, Lowell Satler, William Suddath, Augusto Pichard, Ron Waksman

January 31, 2013

Presentation TCT 2013

Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions

Presenter: Paul Teirstein, Gregg Stone, Ian Meredith, Robert Feldman, Joseph Dens, Abram Rabinowitz, Christophe Dubois, Dominic Allocco, Keith Dawkins

January 31, 2013

Advertisement

Everolimus-eluting Stents in Left Main Disease: The ULMD Florence PCI Registry (with Angiographic Follow-up)

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Synthesis of the ISAR Clinical Trials Comparing Different Stents in Different Settings

SYNTAX COST-EFFECTIVENESS: Final Five-Year Results from a Prospective, Randomized Trial of Paclitaxel-Eluting Stents vs. CABG in Patients with Triple Vessel and Left Main Corona...

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Everolimus-eluting Stents in Left Main Disease: Precombat II 3 Year Results

Dedicated Bifurcation Stents for the Left Main: Experience with Axxess, Tryton and Others

Contra Position: Dedicated Bifurcation Stents are a Historical Cconcept and are No Longer Needed!

Case #2: A Complex Bifurcation: Dedicated Stent, Planned 2 Stents or Provisional Stent strategy?

A Prospective, Randomized Trial of a Paclitaxel-Coated Balloon Plus Bare Metal Stents vs. Paclitaxel-Eluting Stents for De Novo Coronary Lesions

Memories of TCT 1988 and Beyond: Marvin L. Woodall

Cre8, BioFreedom Polymer-Free DES Show Promise

COMFORTABLE AMI: Biolimus-Eluting Stent Bests BMS in STEMI

Bioresorbable Scaffold Stands Ground Next to Current DES

ABSORB III and IV Trials Aim to Prove Superiority of BVS

SFA Stents Can No Longer Be Justified on an Outcomes or Cost Basis!

Management of Patients with Atrial Fibrillation and Stents

Bare Metal and Drug-Eluting Stents: Indications, Outcomes, Complications

The Impact Of First- versus Second-Generation Drug-Eluting Stents On Immediate- and Intermediate-Term Outcomes In A Complex ST-Segment Elevation Myocardial Infarction Population

Two-Year Outcomes Following Implantation of 32mm and 38mm Platinum Chromium Everolimus Eluting Element Stents in Long Coronary Lesions

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content